The role of injectable porcine type I collagen (Tropocollagen) in chronic musculoskeletal disorders.

IF 3.5 3区医学 Q2 RHEUMATOLOGY

Rheumatology International Pub Date : 2026-10-09 DOI:10.1007/s00296-026-06326-7

Kamil Koszela

{"title":"The role of injectable porcine type I collagen (Tropocollagen) in chronic musculoskeletal disorders.","authors":"Kamil Koszela","doi":"10.1007/s00296-026-06326-7","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this narrative review is to present current data on the use of porcine type I collagen (tropocollagen) injections in the treatment of chronic musculoskeletal disorders, with particular emphasis on its clinical application and safety profile. A search was conducted in the Medline/PubMed, Scopus, and Directory of Open Access Journals (DOAJ) databases. Based on inclusion and exclusion criteria, 14 publications were identified. The available studies cover the use of collagen administered intra-articularly, periarticularly, and via mesotherapy. The analyzed publications reported improvements in clinical symptoms and function in various chronic musculoskeletal conditions, accompanied by a favorable safety profile. However, it should be emphasized that the available clinical evidence is limited by small sample sizes, heterogeneity in treatment protocols, and a relatively short follow-up period. Injectable porcine type I collagen is a promising adjunctive treatment for chronic musculoskeletal disorders; however, further, well-designed randomized clinical trials with larger patient cohorts and longer follow-up periods are necessary.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"46 10","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652760/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-026-06326-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of this narrative review is to present current data on the use of porcine type I collagen (tropocollagen) injections in the treatment of chronic musculoskeletal disorders, with particular emphasis on its clinical application and safety profile. A search was conducted in the Medline/PubMed, Scopus, and Directory of Open Access Journals (DOAJ) databases. Based on inclusion and exclusion criteria, 14 publications were identified. The available studies cover the use of collagen administered intra-articularly, periarticularly, and via mesotherapy. The analyzed publications reported improvements in clinical symptoms and function in various chronic musculoskeletal conditions, accompanied by a favorable safety profile. However, it should be emphasized that the available clinical evidence is limited by small sample sizes, heterogeneity in treatment protocols, and a relatively short follow-up period. Injectable porcine type I collagen is a promising adjunctive treatment for chronic musculoskeletal disorders; however, further, well-designed randomized clinical trials with larger patient cohorts and longer follow-up periods are necessary.

查看原文本刊更多论文

可注射猪I型胶原蛋白（Tropocollagen）在慢性肌肉骨骼疾病中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology International 医学-风湿病学

CiteScore

7.30

自引率

5.00%

发文量

191

审稿时长

16. months

期刊介绍： RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology. RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.